IL17A and Hepatic fibrosis: In a mouse model of Bile Duct Ligation (BDL)-induced liver fibrosis, IL-17A antibody therapy reduced hepatocyte necrosis, decreased pro-inflammatory cytokines, and mitigated neutrophil and macrophage infiltration (62).